Towards gene therapy against HIV-1: new therapeutic target in gag RNA accessible to ribozymes and RNA interference molecules
© Gatignol et al; licensee BioMed Central Ltd. 2014
Published: 23 May 2014
Antisense molecules targeting HIV-1 RNA have the potential to be used as part of combination gene or drug therapy to treat HIV-1 infection to reach a functional or complete cure. Only a small number of extremely active molecules currently exist and a treatment option has not yet been identified in clinical trials. We have previously developed new hepatitis delta virus (HDV)-derived ribozymes (Rzs) called "switch on-off adaptor" (SOFA) to target HIV-1 RNA . Our aim is to develop highly active RNA-based molecules with complementary mechanisms, which are able to reach a large number of HIV-1 variants.
We screened HIV-1 RNA to identify conserved target sites for new HDV-Rzs . We designed new SOFA-HDV-Rzs against the Gag RNA and developed a rapid test to evaluate the inhibition of HIV-1 production. We designed small interfering (si) RNAs targeting the same region and tested their activity on HIV-1 replication.
We identified 13 conserved regions in the gag RNA and constructed the corresponding Rzs. We transfected HEK293T cells with these Rzs and HIV-1 molecular clones. We identified one Rz that was particularly efficacious. We then constructed siRNAs and short hairpin (sh) RNAs targeting the same sequence. The shRNA was very active against HIV-1 clades B, C and A/G. Neither the Rz, nor the shRNA disturbs the cellular transcriptome, suggesting no toxicity. In lymphocytic cell lines, both the Rz and the shRNA inhibit long-term HIV-1 replication .
We identified new SOFA-HDV-Rz, siRNA and shRNA targeting HIV-1 Gag RNA. The shRNA is as active as the only shRNA that has advanced to clinical trials and targets more strains. Long-term inhibitory activity of these molecules shows that this site is particularly accessible to other antisense molecules. These molecules have a high potential to be used in combination gene therapy or as drugs with appropriate delivery methods.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.